Literature DB >> 27668856

Tumor microenvironment-mediated chemoresistance in breast cancer.

Kobra Velaei1, Nasser Samadi2, Balal Barazvan3, Jafar Soleimani Rad4.   

Abstract

Therapy resistance or tumor relapse in cancer is common. Tumors develop resistance to chemotherapeutic through a variety of mechanisms, with tumor microenvironment (TM) serving pivotal roles. Using breast cancer as a paradigm, we propose that responses of cancer cells to drugs are not exclusively determined by their intrinsic characteristics but are also controlled by deriving signals from TM. Affected microenvironment by chemotherapy is an avenue to promote phenotype which tends to resist on to be ruined. Therefore, exclusively targeting cancer cells does not demolish tumor recurrence after chemotherapy. Regardless of tumor-microenvironment pathways and their profound influence on the responsiveness of treatment, diversity of molecular properties of breast cancer also behave differently in terms of response to chemotherapy. And also it is assumed that there is cross-talk between phenotypic diversity and TM. Collectively, raising complex signal from TM in chemotherapy condition often encourages cancer cells are not killed but strengthen. Here, we summarized how TM modifies responses to chemotherapy in breast cancer. We also discussed successful treatment strategies have been considered TM in breast cancer treatment.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer; Chemoresistance; Stromal cells; Tumor microenvironment

Mesh:

Substances:

Year:  2016        PMID: 27668856     DOI: 10.1016/j.breast.2016.09.002

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  52 in total

Review 1.  Targeting the tumour stroma to improve cancer therapy.

Authors:  Kenneth C Valkenburg; Amber E de Groot; Kenneth J Pienta
Journal:  Nat Rev Clin Oncol       Date:  2018-06       Impact factor: 66.675

2.  Inhibition of N-acetyltransferase 10 using remodelin attenuates doxorubicin resistance by reversing the epithelial-mesenchymal transition in breast cancer.

Authors:  Ji Wu; Hong Zhu; Jianqiang Wu; Wei Chen; Xiaoqing Guan
Journal:  Am J Transl Res       Date:  2018-01-15       Impact factor: 4.060

3.  Three dimensional engineered models to study hypoxia biology in breast cancer.

Authors:  Vaishali Aggarwal; Oshin Miranda; Paul A Johnston; Shilpa Sant
Journal:  Cancer Lett       Date:  2020-06-20       Impact factor: 8.679

Review 4.  Tumor microenvironment promotes breast cancer chemoresistance.

Authors:  Umar Mehraj; Abid Hamid Dar; Nissar A Wani; Manzoor A Mir
Journal:  Cancer Chemother Pharmacol       Date:  2021-01-09       Impact factor: 3.333

5.  Resistin potentiates chemoresistance and stemness of breast cancer cells: Implications for racially disparate therapeutic outcomes.

Authors:  Sachin K Deshmukh; Sanjeev K Srivastava; Haseeb Zubair; Arun Bhardwaj; Nikhil Tyagi; Ahmed Al-Ghadhban; Ajay P Singh; Donna L Dyess; James E Carter; Seema Singh
Journal:  Cancer Lett       Date:  2017-03-14       Impact factor: 8.679

6.  High-background parenchymal enhancement in the contralateral breast is an imaging biomarker for favorable prognosis in patients with triple-negative breast cancer treated with chemotherapy.

Authors:  Chuanhui Xu; Jinhui Yu; Feifei Wu; Xuemei Li; Dongmin Hu; Guiming Chen; Gang Wu
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

7.  IL6 derived from cancer-associated fibroblasts promotes chemoresistance via CXCR7 in esophageal squamous cell carcinoma.

Authors:  Y Qiao; C Zhang; A Li; D Wang; Z Luo; Y Ping; B Zhou; S Liu; H Li; D Yue; Z Zhang; X Chen; Z Shen; J Lian; Y Li; S Wang; F Li; L Huang; L Wang; B Zhang; J Yu; Z Qin; Y Zhang
Journal:  Oncogene       Date:  2017-10-23       Impact factor: 9.867

8.  Cytokines secreted by stromal cells in TNBC microenvironment as potential targets for cancer therapy.

Authors:  Marie K Malone; Karly Smrekar; Sunju Park; Brianna Blakely; Alec Walter; Nicholas Nasta; Jay Park; Michael Considine; Ludmila V Danilova; Niranjan B Pandey; Elana J Fertig; Aleksander S Popel; Kideok Jin
Journal:  Cancer Biol Ther       Date:  2020-03-26       Impact factor: 4.742

Review 9.  Microengineered 3D Tumor Models for Anti-Cancer Drug Discovery in Female-Related Cancers.

Authors:  Farbod Amirghasemi; Emmanuela Adjei-Sowah; Barbara A Pockaj; Mehdi Nikkhah
Journal:  Ann Biomed Eng       Date:  2021-01-05       Impact factor: 3.934

10.  Unveiling the immune infiltrate modulation in cancer and response to immunotherapy by MIXTURE-an enhanced deconvolution method.

Authors:  Elmer A Fernández; Yamil D Mahmoud; Florencia Veigas; Darío Rocha; Matías Miranda; Joaquín Merlo; Mónica Balzarini; Hugo D Lujan; Gabriel A Rabinovich; María Romina Girotti
Journal:  Brief Bioinform       Date:  2021-07-20       Impact factor: 11.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.